Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE YOUNG: CagriSema versus placebo in children and adolescents with type 2 diabetes
MOH_2026-03-18_015721Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CagriSema, cagrilintide and semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2026-03-18_015721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-18_015721.